MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
AcelRx Pharmaceuticals Interest Expense 2011-2026 | ACRX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 134 K | 1.12 M | 2.29 M | 3.3 M | 2.54 M | 2.22 M | 3.32 M | 2.77 M | 2.98 M | 2.64 M | 1.52 M | 2.28 M | 2.31 M | 1.4 M | 1.24 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.32 M | 134 K | 2.14 M |
Quarterly Interest Expense AcelRx Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 15 K | 119 K | - | 245 K | 293 K | 390 K | - | 538 K | 614 K | 672 K | - | 824 K | 872 K | 855 K | - | 828 K | 500 K | 376 K | - | 529 K | 586 K | 643 K | - | 919 K | 903 K | 774 K | - | 702 K | 687 K | 680 K | - | 713 K | 777 K | 806 K | - | 816 K | 530 K | 472 K | - | 348 K | 403 K | 454 K | - | 573 K | 598 K | 594 K | - | 377 K | 156 K | 1.36 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.36 M | 15 K | 593 K |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
496 K | $ 5.87 | 6.53 % | $ 87.2 M |  USA |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
501 K | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
DURECT Corporation
DRRX
|
2.4 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-241 K | $ 2.74 | 0.37 % | $ 1.05 B | Canada |
 |
Harrow Health
HROW
|
47 K | $ 33.0 | 0.12 % | $ 1.21 B | USA |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
-5 K | $ 2.66 | - | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
-373 K | $ 23.35 | -0.55 % | $ 1.08 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
-142 M | $ 5.47 | 0.37 % | $ 2 B | Canada |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.04 | -2.8 % | $ 112 M | Canada |
 |
Tilray
TLRY
|
46.6 M | $ 5.29 | -3.11 % | $ 3.27 B | Canada |
 |
Solid Biosciences
SLDB
|
824 K | $ 6.62 | 1.85 % | $ 579 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 1.1 | 3.77 % | $ 1.37 M | USA |
 |
Jupiter Wellness
JUPW
|
152 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-539 K | $ 6.09 | -5.58 % | $ 393 M | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.45 | -1.36 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
54.2 M | $ 8.45 | 0.96 % | $ 433 M | USA |
 |
Veru
VERU
|
768 K | $ 2.35 | 5.86 % | $ 34.4 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
34.3 K | $ 0.76 | -2.32 % | $ 3.06 M | USA |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 23.44 | 0.3 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
764 K | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 7.04 | -2.36 % | $ 278 M | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 0.73 | 3.0 % | $ 36.5 M | USA |
 |
Viatris
VTRS
|
471 M | $ 16.65 | 1.15 % | $ 19.4 B | USA |
 |
Zomedica Corp.
ZOM
|
-144 K | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
27 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-623 K | $ 0.79 | -2.06 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
27.3 K | $ 0.76 | -0.29 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
300 K | $ 2.12 | 0.47 % | $ 24.5 M | USA |